The Week Ahead In Biotech: FDA Decision On G1 Therapeutics, Earnings In The Mix For Light Calendar Week


Laboratory Test Tubes

Image Source: Unsplash

Biotech stocks advanced in the week ended Feb. 12, thanks to broader market strength and company-specific catalysts. Small and mid-cap earnings, multiple conference presentations, data readouts, and a slew of IPOs were all part of the week's news flow.

Regeneron Pharmaceuticals Inc (REGN) received two FDA approvals during the week. Immunotherapy Libtayo, which the company co-developed with Sanofi SA (SNY), got a label expansion as a treatment option for basal cell carcinoma. Regeneron also received the nod for its Evkeeza, as an adjunctive treatment option for ultra-rare cholesterol disease.

Ocugen Inc (OCGN) and Kalvista Pharmaceuticals Inc (KALV) were among the best performing stocks of the week. The former moved on momentum gathered on the back of a U.S. COVID-19 vaccine deal with Bharat Biotech and the news of an offering priced at a premium. Kalvista gained on a positive data readout.


  • BIO CEO & Investor Digital Conference: Feb. 16-18.


The FDA is set to rule on G1 Therapeutics Inc (GTHX)'s new drug application for trilaciclib as a treatment option for mitigating the impact of chemotherapy in small-cell lung cancer. The PDUFA date by which the verdict has to be issued is Monday, Feb. 15.


Monday, Feb. 15:

  • Medpace Holdings Inc (MEDP).

Tuesday, Feb. 16:

  • Zoetis Inc (ZTS) (before the market open).
  • EXACT Sciences Corporation (EXAS) (after the market close).

Wednesday, Feb. 17:

  • Royalty Pharma plc (RPRX) (before the market open).
  • Ironwood Pharmaceuticals, Inc. (IRWD) (before the market open).
  • Blueprint Medicines Corp (BPMC) (before the market open).
  • 10X Genomics Inc (TXG) (after the close).
  • Invitae Corp (NVTA) (after the close).
  • Globus Medical Inc (GMED) (after the close).
  • Shockwave Medical Inc (SWAV) (after the close).
  • Veracyte Inc (VCYT) (after the close).
  • Viking Therapeutics Inc (VKTX) (after the close).
1 2
View single page >> |

© 2021 Benzinga does not provide investment advice. All rights reserved.

How did you like this article? Let us know so we can better customize your reading experience.


Leave a comment to automatically be entered into our contest to win a free Echo Show.